VIDAS^® Acute Coronary Syndrome panel

The VIDAS^® Acute Coronary Syndrome (ACS) panel offers three complementary tests for the assessment of myocardial injury^{1, 2}. Performed on the instruments of the VIDAS^® family, these assays are particularly suitable for emergency testing.

Complementary markers for the diagnosis of acute myocardial infarction (AMI)

Cardiac Troponin I (cTnI) is the preferred biomarker of cardiac necrosis due to its specificity for myocardial tissue damage². A rapid increase of cTnl levels (within 3 to 6 hours after the onset of chest pain) and the fact they remain elevated for 4 to 7 days⁵ give cTnI high diagnostic value for myocardial infarction.

The protein concentration of the MB isoenzyme of human creatine kinase (CK-MB) is recommended for the diagnosis of myocardial infarction when cardiac troponin assays are not available⁵. CK-MB also increases rapidly after infarction. Due to its shorter half-life, it can be used as a marker for re-infarction.

Myoglobin is one of the first markers of myocardial damage to be measured after the onset of myocardial infarction. For patients presenting within 6 hours of the onset of symptoms, it may be considered in addition to cardiac troponin for rule-out⁵.

cardiac_necrosis_markers_after_ami.jpg

Temporal profile of cardiac necrosis markers after acute myocardial infarction
(adapted from [6]).

Clinical sensitivity and specificity of VIDAS^® Troponin I Ultra

Clinical performance of VIDAS^® Troponin I Ultra for patients presenting with symptoms suggestive of ACS^*:

troponin_i_ultra_99cv_cut-off_.jpg

Clinical Performance (using the 99^th percentile cut-off: 0.01µg/L)³
 

troponin_i_ultra_10cv_cut-off.jpg

Clinical Performance (using the 10%CV cut-off: 0.11µg/L)⁷
 

VIDAS^® solution benefits

• Reliable and easy-to-use instruments with random access and small foot-print. Well adapted to rapid response laboratories.
• Factory-calibrated, single-dose tests which reduce the need for additional controls^**.
• Short time to result: VIDAS Troponin I Ultra result available in only 20 minutes; comparable assay times for VIDAS CK-MB and Myoglobin.
• Reagents can be used immediately after removal from the refrigerator.
• VIDAS NT-proBNP2 available on the same platform.

* Please consult our local subsidiary or representatives for the availability of these products in your country.
** Depending on local guidelines.

References:

1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32: 2999-3054.
2. Thygesen K, Alpert JS, Jaffe AS, et al., the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567
3. Apple FS, Smith SW, Pearce LA, et al. Use of the bioMérieux VIDAS® troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms of acute coronary syndrome. Clin Chem Acta 2008;390:72-75.
4. Venge, P and Lindahl, B. Cardiac Troponin Assay Classification by Both Clinical and Analytical Performance Characteristics: A Study in Outcome Prediction. Clin Chem 2013;59:976-81.
5. Morrow, DA, Cannon CP, Jesse JL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; 115: 356-75.
6. Wu AH, Apple FS, Gibler WB et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. 1999; 45: 1104-1121.
7.  Package insert, VIDAS Troponin I Ultra (TNIU), CE-mark. August 2010.